MIMEDX GROUP, INC.

(MDXG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

12/07/2021 | 12:48pm EDT

Item 7.01 Regulation FD

On Tuesday, December 7, 2021, MiMedx Group, Inc. (the "Company" or "MiMedx"), held a virtual Investors Day at 9:00 a.m. Eastern Time. A copy of the presentation materials used, together with a press release issued and a letter to shareholders published by Timothy R. Wright, Chief Executive Officer of the Company, in connection with the Investors Day, are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and are incorporated herein for reference. These materials shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section and shall only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No.              Description of Exhibit
99.1                       Slide Presentation dated December 7, 2021
99.2                       Press release dated December 7, 2021
99.3                       Letter to Shareholders dated December 7, 2021
                         The cover page from this Current Report on Form 8-K, formatted in Inline
104                      XBRL.

© Edgar Online, source Glimpses

All news about MIMEDX GROUP, INC.
05/16MIMEDX Mails Letter to Shareholders
AQ
05/10TRANSCRIPT : MiMedx Group, Inc. Presents at Bank of America 2022 Healthcare Conference, Ma..
CI
05/10MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
05/10MIMEDX Comments On Prescience Point's False And Misleading Statements
AQ
05/09Prescience Point Capital Management LLC Provides Information to Shareholders of MiMedx ..
CI
05/09MIMEDX Comments on Prescience Point's False and Misleading Statements
AQ
05/09MIMEDX Group, Inc Comments on Prescience Point Capital Management Statements
CI
05/06Prescience Point Capital Management Issues Open Letter to Shareholders of MiMedx Group
PR
05/06Prescience Point Capital Management LLC Issues Open Letter to Shareholders of MiMedx Gr..
CI
05/05MIMEDX to Participate at Upcoming Investor Conferences
AQ
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2022 273 M - -
Net income 2022 -24,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -17,9x
Yield 2022 -
Capitalization 430 M 430 M -
Capi. / Sales 2022 1,57x
Capi. / Sales 2023 1,38x
Nbr of Employees 811
Free-Float 97,9%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MDXG | US6024961012 | MarketScreener
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,82 $
Average target price 14,17 $
Spread / Average Target 271%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Scott M. Turner Vice President-Procurement
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-36.75%436
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
MODERNA, INC.-45.70%54 855
WUXI APPTEC CO., LTD.-16.67%43 023